Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Crohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 Dec 2014 Planned End Date changed from 1 Jul 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov.
- 18 Nov 2011 Additional trial identifier 2010-566 identified as reported by ClinicalTrials.gov.